tbuckley/cabot-search huggingface dataset:
Abstract 16306: Preserved Ejection Fraction and Patient Comorbidities in the Outpatient Clinics of the Canadian Heart Failure Network
Authors: J. Malcolm Arnold, Jonathan Howlett, Peter Liu, Marie-Helene Leblanc, Andy Ignaszewski, Annemarie Kaan, Miroslaw Rajda, Michael Chan, David Bewick, Gord Marchiori
Journal: Circulation (2011)

While heart failure (HF) often presents with similar symptoms and signs, the etiology and accompanying comorbidities can be very different among patients. Although we have evidence based treatments...
Couverture vaccinale contre la grippe chez les personnes âgées en Campanie (Italie) en 1999
Authors: P D'Argenio, B Adamo, R Coluccio, A D'Apice, M. A. Ferrara, F Giugliano, R Parrella, F Peluso, V Romeo, C Ronga, A Simonetti, A Citarella
Journal: Eurosurveillance (2001)

Une etude sur la couverture vaccinale contre la grippe chez les personnes âgees a ete menee. Cinquante-six pour cent des personnes interrogees ont ete vaccinees (taux de vaccination pondere de 50%), alors que l’objectif vise etait de 75%. Cependant les taux de vaccination etaient superieurs chez les plus de 74 ans et ceux atteints de maladies chroniques.
Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
Authors: Archana Thakur, Lawrence G Lum, Vidya Kondadasule, Ritesh Rathore, Zaid Al-Kadhimi, Elyse Tomaszewski, Dana Schalk, Joseph Uberti, Voravit Ratanatharathorn
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Despite improvements in treatment options, metastatic breast cancer (MBC) remains an incurable disease. In our recent Phase I immunotherapy (IT) trial in 23 women with MBC, 8 infusions of activated T cells (ATC) armed with anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) given in
Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease.
Authors: J J Grantham, M Ye, C Davidow, B Holub, M Sharma
Journal: Journal of the American Society of Nephrology (1995)

Transepithelial fluid secretion appears to be an important factor in the progressive enlargement of cysts in autosomal dominant polycystic kidney disease. Evidence indicates that the fluid within cysts harbors an autocrine, paracrine, or endocrine secretagogue with the capacity to modulate the rate of cyst expansion. Fluids from five patients with autosomal dominant polycystic kidney disease were studied to determine the chemical nature and the physiologic function of the putative secretagogue. The secretory activity of cyst fluid assayed with polarized monolayers of Madin Darby canine kidney cells could be ascribed to a lipophilic substance of molecular weight < 3,500 d that was not destroyed by freezing, boiling, or proteolytic digestion. This lipid stimulated the production of intracellular cAMP and increased the rate of fluid secretion when added to either surface of cultured renal epithelial cells. Anion exchange chromatography revealed biologic secretory activity to a greater extent in the neutral lipid than in the fatty acid and phospholipid fractions separated from cyst fluid. More extensive chromatographic separation showed preferential appearance of the secretagogue in a fraction of neutral lipids enriched in monoglycerides. Among several candidate lipids, 1-mono-arachidonyl glyceride and arachidonic acid were found to mimic the effect of the cyst fluid to stimulate fluid secretion by Madin Darby canine kidney cells; however, their abundance in cyst fluid was insufficient to account for the degree to which secretion was stimulated by cyst fluid. Moreover, the effect of the arachidonic acid species to stimulate fluid secretion was inhibited by treatment with indomethacin, whereas the effect of the cyst fluid was not. On the basis of this study, it was concluded that human autosomal dominant polycystic kidney disease cyst fluid contains an anonymous lipid with the capacity to stimulate fluid secretion in renal epithelia. This potent endogenous modulator of fluid transport may have an important role in determining the rate at which cysts expand in autosomal dominant polycystic disease.
Gradual evolution of a specific satellite DNA family in Drosophila ambigua, D. tristis, and D. obscura.
Authors: L Bachmann, D Sperlich
Journal: Molecular Biology and Evolution (1993)

The highly repetitive satellite DNA family "ATOC180" is specific for the three closely related species Drosophila obscura, D. ambigua, and D. tristis but does not occur in their closest relatives D. subsilvestris and D. bifasciata. Approximately 10,000 copies/haploid genome of approximately 180-bp repetition units are tandemly arranged in the centromeric heterochromatin of all chromosomes of all three species. Molecular analysis of 29 cloned repeats shows much intra- and interspecific sequence homogeneity. Single nucleotide changes are the main source of variability and distinguish the sequence-, subfamily- and species-specific ATOC180 repeats from each other. Based on these nucleotide differences, phylogenetic dendrograms were constructed and compared with published trees for other traits. The data indicate that the sequences of the ATOC180 satellite DNA family probably arose in a phylogenetically "short period" during the anagenetic evolution of the common ancestor of D. obscura, D. tristis, and D. ambigua, as a consequence of a process of genome reorganization, followed by a "long period" of entirely gradual sequence evolution. For the latter period, an evolutionary rate of 3 x 10(-8) substitutions/site/year was calculated.
RNA stabilization of human whole bone marrow aspirates for high reliability of gene expression analysis
Authors: Kalle Guenther, Claudia Langebrake, Juergen Lauber, Dirk Reinhardt
Journal: Cancer Research (2007)

2713    Introduction:  Gene expression analysis of human bone marrow (BM) is a useful tool for the diagnosis and research of cancer and disease monitoring. One of the major challenges for reliable analysis is the alteration of gene expression starting immediately at the time of aspiration, even after short-term storage of native specimens, due to  ex vivo  gene induction, repression, and RNA degradation.  The objective of this study was to investigate and compare the performance of the newly developed and recently launched PAXgene™ Bone Marrow RNA System (For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the dagnosis, prevention, or treatment of a disease.) to a commonly used protocol.   Patients and methods:  A total of 45 heparinized BM specimen of unselected children with acute leukemia at initial diagnosis, during treatment or without pathological findings in hematopoiesis, were aspirated and immediately divided into two PAXgene Bone Marrow RNA Tubes and 2 EDTA tubes each. RNA preparation using either the PAXgene Bone Marrow RNA Kit or a reference protocol was performed within 2 hours or after 48 hours of storage at room temperature. The resulting total of 180 RNA samples were subjected to UV spectroscopy, capillary gel electrophoresis (RIN calculation), and real-time RT-PCR of GATA1, RUNX1, NCAM, SPI1.   Results:  The overall RNA yield (normalized to 1x10 7  leukocytes) was not different in all four samples per specimen. However the RNA integrity using the PAXgene System was significantly higher at both time-points than that of reference system: 8.6±0.2 vs. 6.8±0.4, p=0.0003 and 8.1±0.2 vs. 6.7±0.5, p=0.008. The PAXgene System showed high reliability with no failures in sample processing and good pairwise correlation in gene expression for each gene at 48 compared to 2 hours: GATA1 89±6%, RUNX1 83±10%, NCAM 69±12% and SPI1 89±6%. Significant differences were detected in 2 of the analyzed genes using the reference procedure: 40±6%, p   Conclusions:  The PAXgene Bone Marrow RNA System (RUO) enables the collection, stabilization, storage, and transportation of human BM specimens, together with a rapid and efficient protocol for isolation and purification of cellular RNA. It provides significant stabilization of gene expression patterns in comparison to significant changes of transcript levels using a common reference method. RNA was stabilized in PAXgene Bone Marrow RNA Tubes for two days at room temperature with essentially higher RNA integrity than the reference method.  In conclusion, the PAXgene Bone Marrow RNA System is appropriate for minimizing variations of gene expression in clinical BM specimen. It provides high quality and quantity of RNA, suitable for molecular downstream applications such as real-time RT-PCR.
Public health implications of an outbreak of rabies in arctic foxes and reindeer in the Svalbard archipelago, Norway, September 2011
Authors: E MacDonald, K Handeland, H Blystad, M Bergsaker, M Fladberg, B Gjerset, O Nilsen, H Os, S Sandbu, E Stokke, L Vold, I Ørpetveit, H Gaup Åmot, O Tveiten
Journal: Eurosurveillance (2011)

Between 16 September and 5 October 2011 rabies was diagnosed in two arctic foxes and eight reindeer in the Svalbard archipelago, in Norway. This outbreak occurs at the end of the reindeer hunting season and poses an increased risk to many people that were involved in the hunt. As of 28 September 2011, 280 people had received post-exposure prophylaxis. No human cases of rabies have occurred.
Recurrence of focal segmental glomerulosclerosis posttransplantation
Authors: A Tejani, D H Stablein
Journal: Journal of the American Society of Nephrology (1992)

Among various forms of glomerulonephritis, focal segmental glomerulosclerosis (FSGS) is the most common cause of end-stage renal disease leading to transplantation in children. Previous reports of the recurrence of FSGS vary widely. The North American Pediatric Renal Transplant Cooperative Study carried out a special study to determine the rate of recurrence and risk factors leading to recurrence in 132 transplants. Fifty-five percent of the patients were white children, and the remaining were black and Hispanic children. Fifty percent of the patients were under 5 yr of age at the time of the diagnosis of FSGS. Twenty-seven (20.5%) of 132 patients (95% confidence interval, 14 to 27) had a biopsy-proven recurrence of FSGS. The median time to recurrence was 14 days. The recurrence rate was similar in white children (23%) when compared with that in Hispanic children (20%) but was lower than that in black children (9%) (3 of 32 children).2+ (20%). The mean serum albumin level of patients with recurrence was 1.7 versus 2.0 g/dL for those without recurrence. The mean serum cholesterol level of patients with recurrence was 525 versus 476 mg/dL for those without recurrence. The duration of dialysis was similar in the two groups. The mean time from diagnosis to end-stage renal disease status was 33 months for patients with recurrence and 52 months for those without recurrence (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign
Authors: P. Barozzi, M. Luppi, K. Cagossi, A. Maiorana, R. Marasca, T. Artusi, S. Poggi, S.A. Pileri, G. Torelli
Journal: Annals of Oncology (1999)
New Approaches for Melanoma
Authors: Rebecca Voelker
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic muscularis excavation of a rectal duplication cyst
Authors: Hrvoje Ivekovic, Branko Bilic, Jasminka Jakic Razumovic, Mirjana Kalauz, Nadan Rustemovic, Hubert Piessevaux, Pierre Deprez
Journal: Endoscopy (2015)

Rectal duplication cyst (RDC) is a rare congenital disorder of the hindgut, accounting for up to 5 % of all duplications in the alimentary tract [1] . The cyst usually becomes apparent in childhood, presenting with infection, fistulization, or mass effect; clinical presentation in adulthood is uncommon. Surgical excision is a cornerstone of treatment because it relieves symptoms and prevents complications, such as perianal sepsis, bleeding, and malignant degeneration [2] . Herein, we describe what is, to the best of our knowledge, the first case of endoscopic resection of an RDC.
The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives
Authors: K.I. Pritchard
Journal: Annals of Oncology (2001)

Estrogen replacement therapy either with (HRT) or without (ERT) accompanying progesterone is routinely offered to well women at the time of menopause, in order to relieve vasomotor symptoms, (hot flashes), reduce urogenital atrophy and reduce the risks of cardiovascular disease, osteoporosis and perhaps colon cancer and Alzheimer's disease. It is generally felt however, that women with a previous diagnosis of breast cancer are not suitable candidates for such therapy since either estrogen or progesterone may be associated with an increased risk of cancer recurrence. There are however, a variety of approaches to menopausal therapy in such women. A careful history must first be taken in order to identify the symptoms or conditions of concern. Vasomotor symptoms can be reduced by the use of other medications such as the antidepressant venlafaxine (Effexor). Estring, a vaginal estrogen ring can be used to reduce genitourinary symptoms, with little systemic estrogen absorption. Osteoporosis can be prevented or treated with calcium supplements, exercise, improved diet, bisphosphonates and/or selective estrogen receptor modulators (SERMs) while cardiovascular risk can be reduced by diet and exercise, as well as the appropriate use of lipid lowering and antihypertensive medications.
Annual HIV incidence fell by a third from 2000 to 2014
Authors: Anne Gulland
Journal: BMJ (2015)

The annual number of adults and children newly infected with HIV fell from 3.1 million in 2000 to 2.1 million in 2014, show new figures released by the World Health Organization for world AIDS day on 1 December.1

The decline in the number of new infections was even steeper in Africa, which saw a 40% drop (from 2.3 million to 1.4 million) over the same period.

The number of people receiving treatment has also increased substantially, with an estimated 16 million taking antiretrovirals in 2014, 11 million of whom were in Africa. In 2000 …
Briquet's syndrome, hysterical personality, and the MMPI
Authors: B I Liskow, P Clayton, R Woodruff, S Guze, R Cloninger
Journal: American Journal of Psychiatry (1977)

The authors compared the MMPI scores of 29 inpatients diagnosed by other authors as having hysterical personality and 21 outpatients diagnosed by the authors as having Briquet's syndrome. The two groups of patients differed significantly in age, on the MMPI lie scale, and on the MMPI hypochondriasis scale but not on any of the other MMPI scales. The authors discuss the implications of these findings for further defining the differences and similarities between hysterical personality and Briquet's syndrome.
Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma
Authors: Matthew Zibelman, Anthony Olszanski
Journal: Journal of the National Comprehensive Cancer Network (2014)

Metastatic melanoma is a devastating disease that has been increasing in incidence and until relatively recently had few effective treatment options. With the approval in 2011 of ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte associated protein 4 (CTLA-4), however, that has begun to change. Ipilimumab is an immune checkpoint inhibitor, a type of immunotherapy that can down-regulate inhibitory signals affecting T-cell activation to unleash more dramatic anti-tumoral responses and offer the possibility of deep and durable remissions in up to 20% of patients. Use of this and similar agents can lead to characteristic and varied immune-related adverse events (irAEs); however, experience has shown that these can be managed with patient education, early recognition, and judicious use of systemic steroids. Newer immune checkpoint inhibitors such as those that block PD-1 or PDL-1 have shown impressive results in early studies. Most recently, pembrolizumab, an anti-PD-1 antibody, was approved by the FDA for the treatment of patients with melanoma after progression on a CTLA-4 inhibitor and, if clinically relevant, a BRAF inhibitor. This supplement presents the case of a 60-year-old man with an enlarging right neck mass who was found to have disseminated metastatic melanoma. He was started on treatment with the CTLA-4 inhibitor ipilimumab (3 mg/kg intravenous). After the third dose, the patient developed grade 3 uveitis/retinitis and immune-mediated nephritis requiring hospitalization and systemic corticosteroids. Both conditions were considered irAEs secondary to ipilimumab. The patient recovered completely from all toxicities but did not receive further doses of ipilimumab. Nonetheless, the patient experienced a complete radiographic response and at time of writing was 19 months from diagnosis without evidence of disease.
Linear Scars in a 4-Week-Old Girl
Authors: Oana-Diana Persa, Judith Fischer, Iliana Tantcheva-Poór
Journal: JAMA Dermatology (2015)

A 4-week-old girl who had erosions on the left leg, left side of the neck, abdomen, and left ear at birth presented with linear scars. Clinical examination revealed erythematous atrophic streaks along Blaschko lines and soft skin-colored papules on the left leg. What is your diagnosis?
Complete Response of Adult-Onset CNS Langerhans Cell Histiocytosis Documented on 18F-FDG PET/CT
Authors: Ivan Kruljac, Antonija Balenović, Petar Gaćina, Shinsaku Imashuku, Milan Vrkljan
Journal: Clinical Nuclear Medicine (2015)

We report a case of a 49-year-old woman with biopsy-proven multisystemic Langerhans cell histiocytosis (LCH) with hypothalamic involvement documented on F-FDG PET/CT. Chemotherapy with a combination of vinblastine, prednisolone, methotrexate, and 6-mercaptopurine was carried out. Two months later, a 90% reduction of the hypothalamic tumor mass was noted on magnetic resonance imaging, but with no signs of pathological F-FDG accumulation. The patient died 4 months later, and we found no signs of LCH on autopsy. Our case highlights the need for further studies regarding the role of F-FDG PET/CT in the assessment of treatment response in patients with LCH.
Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens
Authors: Ken-ichi Hanada, Christopher Chow, Raul Gil Hoyos, Jared J Gartner, Todd D Prickett, Robert Somerville, Katherine Hogan, Paul F Robbins, Steven A Rosenberg, James C Yang
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Patients with metastatic melanoma can be successfully treated with adoptive transfer of tumor infiltrating lymphocytes (TIL). In 93 patients with over 5 year follow-up, the overall response rate was 56% and 20% achieved durable complete responses persisting in excess of 7 years.
Mania in two sisters with similar cerebellar disturbance
Authors: K G Yadalam, A K Jain, G M Simpson
Journal: American Journal of Psychiatry (1985)

The authors describe two sisters who presented with a clinical picture consistent with mania. On further investigation, both had marked vermian and cerebellar cortical atrophy on CAT scans. Their mother also had a history suggestive of cerebellar disease. To the authors' knowledge, this is the first report of familial cerebellar disease with a clinical presentation of mania.
Cervical Cancer
Authors: Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, Sachin M Apte, Susana M Campos, John Chan, Kathleen R Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J Eifel, David K Gaffney, Robert L Giuntoli, Ernest Han, Warner K Huh, John R Lurain, Lainie Martin, Mark A Morgan, David Mutch, Steven W Remmenga, R Kevin Reynolds, William Small, Nelson Teng, Todd Tillmanns, Fidel A Valea, Nicole R McMillian, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2013)

These NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer focus on early-stage disease, because it occurs more frequently in the United States. After careful clinical evaluation and staging, the primary treatment of early-stage cervical cancer is either surgery or radiotherapy. These guidelines include fertility-sparing and non-fertility-sparing treatment for those with early-stage disease, which is disease confined to the uterus. A new fertility-sparing algorithm was added for select patients with stage IA and IB1 disease..
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region
Authors: Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, William I. Gradishar
Journal: Journal of the National Comprehensive Cancer Network (2010)

Published data from the Middle East and North Africa (MENA) region indicate suboptimal quality of cancer care, while the World Health Organization predicts an increase in cancer cases in developing countries. Major advances in breast cancer management mandate the development of guidelines to improve the quality and efficacy of oncology practice in the MENA region. A Breast Cancer Regional Guidelines Committee was organized and activated, comprising experts from various regional cancer institutions. The multidisciplinary team included 12 medical oncologists, 3 radiation oncologists, 2 radiologists, 2 surgeons, and 1 pathologist. The committee members agreed on adapting the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Breast Cancer for use in the MENA region to achieve common practice standards for treating patients. The members suggested several modifications to the guidelines, especially those related to risk factor profiles. United States–based NCCN experts reviewed these recommendations before final approval. The MENA–NCCN Breast Cancer Guidelines modification process was the first initiative in the development of common practice guidelines in the region. This project may serve as a foundation for the development of evidence-based practice standards, and improve collaborative projects and initiatives.